Abstract
Human transferrin receptor 1 (TfR1) is expressed on malignant cells at levels several fold higher than those on normal cells and its expression can be correlated with tumor stage or cancer progression. It is a potentially rational target for drug delivery. To identify novel ligands which can recognize the TfR1 specifically, a random phage displayed 12-mer peptide library was screened and two consensus motifs of the peptides which are displayed by the positive phages RXR and RXXXR (x is any amino acid) were yield. The phage displaying peptide SPRPRHTLRLSL (designated as B18) exhibited the highest affinity to TfR1 in phage ELISA and B18 could bind to TfR1 specifically in a dose dependent manner. The flow cytometry assay and immunocellularchemistry assay showed that the B18 could bind to TfR1 positive carcinoma cells with specificity. In addition, the biodistribution assay indicated that B18 could home to TfR1 positive tumor tissue specifically. Our study suggests that the peptide exhibited by B18 is a potentially promising targeting peptide for tumor diagnosis and treatment.
Keywords: TfR1, phage display, peptide, malignant cells, normal cells, tumor, cancer progression, flow cytometry assay
Protein & Peptide Letters
Title:Identification of a Novel Peptide Ligand of Human Transfrrin Receptor 1 for Targeted Tumor Delivery Drug
Volume: 20 Issue: 1
Author(s): Qin Xin, Zhang Cun, Xue Xiaochang, Li Meng, Li Weina, Hao Qiang, Zhang Yingqi, Yan Zhen and Zhang Wei
Affiliation:
Keywords: TfR1, phage display, peptide, malignant cells, normal cells, tumor, cancer progression, flow cytometry assay
Abstract: Human transferrin receptor 1 (TfR1) is expressed on malignant cells at levels several fold higher than those on normal cells and its expression can be correlated with tumor stage or cancer progression. It is a potentially rational target for drug delivery. To identify novel ligands which can recognize the TfR1 specifically, a random phage displayed 12-mer peptide library was screened and two consensus motifs of the peptides which are displayed by the positive phages RXR and RXXXR (x is any amino acid) were yield. The phage displaying peptide SPRPRHTLRLSL (designated as B18) exhibited the highest affinity to TfR1 in phage ELISA and B18 could bind to TfR1 specifically in a dose dependent manner. The flow cytometry assay and immunocellularchemistry assay showed that the B18 could bind to TfR1 positive carcinoma cells with specificity. In addition, the biodistribution assay indicated that B18 could home to TfR1 positive tumor tissue specifically. Our study suggests that the peptide exhibited by B18 is a potentially promising targeting peptide for tumor diagnosis and treatment.
Export Options
About this article
Cite this article as:
Xin Qin, Cun Zhang, Xiaochang Xue, Meng Li, Weina Li, Qiang Hao, Yingqi Zhang, Zhen Yan and Wei Zhang, Identification of a Novel Peptide Ligand of Human Transfrrin Receptor 1 for Targeted Tumor Delivery Drug, Protein & Peptide Letters 2013; 20 (1) . https://dx.doi.org/10.2174/0929866511307010096
DOI https://dx.doi.org/10.2174/0929866511307010096 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Alternative Approaches to the Discovery and Development of Telomerase- Targeted Anticancer Drugs
Mini-Reviews in Medicinal Chemistry Chemistry and Biological Activity of [1,2,3]-Benzotriazine Derivatives
Current Organic Chemistry Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Editorial (Hot Topic: miRNA in the Pathogenesis and Therapy for Gastrointestinal and Hepatic Cancers)
Current Pharmaceutical Design Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds
Current Neuropharmacology Carbon Nanotubes: Classification, Method of Preparation and Pharmaceutical Application
Current Drug Delivery TGFβ Signaling in Liver Regeneration
Current Pharmaceutical Design Induced Stem Cells as a Novel Multiple Sclerosis Therapy
Current Stem Cell Research & Therapy Origins and Consequences of AID Expression in Lymphoid Neoplasms
Current Immunology Reviews (Discontinued) The Inhibitor of Growth (ING) Gene Family: Potential Role in Cancer Therapy
Current Cancer Drug Targets The Role of SHP-2 in Cell Signalling and Human Disease
Current Enzyme Inhibition Non-Photoinduced Biological Properties of Verteporfin
Current Medicinal Chemistry Overcoming the Challenges of siRNA Delivery: Nanoparticle Strategies
Current Drug Delivery Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
Current Medicinal Chemistry Matrix Metalloproteinases
Current Medicinal Chemistry NADPH Oxidases NOXs and DUOXs as Putative Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry World Health Organization Classification of Myelodysplastic Syndromes
Current Pharmaceutical Design <i>In Silico</i> Study of Potential Cross-Kingdom Plant MicroRNA Based Regulation in Chronic Myeloid Leukemia
Current Pharmacogenomics and Personalized Medicine Wnt / β-Catenin Signaling Pathway as Novel Cancer Drug Targets
Current Cancer Drug Targets Development of Genomics-Based Gene Expression Signature Biomarkers in Oncology and Toxicology to Facilitate Drug Discovery and Translational Medicine
Current Bioinformatics